← all works
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- PARP inhibition in cancer therapy
- Field
- Medicine
- Canadian institutions
- Princess Margaret Cancer CentreOttawa HospitalUniversity Health Network
- Funders
- Janssen BiotechNational Cancer InstituteStand Up To CancerEMD SeronoGenentechImmunoGenAjinomotoClovis OncologyAmgenAmerican Association for Cancer ResearchNational Ovarian Cancer CoalitionRegeneron PharmaceuticalsUniversity College LondonCancer Research UKArray BioPharmaMemorial Sloan-Kettering Cancer CenterAjinomoto PharmaceuticalsRocheAbbVieMerckOvarian Cancer Research FundAstraZenecaOncoMed PharmaceuticalOvarian Cancer Research Fund AllianceU.S. Department of Defense
- Keywords
- MedicinePlaceboOncologyInternal medicineOvarian carcinomaDouble blindOvarian cancerSurgeryCancerAlternative medicinePathology
- Has abstract in OpenAlex
- no